CBIO
Crescent Biopharma
CBIO
CBIO
58 hedge funds and large institutions have $416M invested in Crescent Biopharma in 2017 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 25 increasing their positions, 15 reducing their positions, and 16 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
more funds holding in top 10
Funds holding in top 10: →
less ownership
Funds ownership: →
16% less funds holding
Funds holding: 69 → 58 (-11)
63% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 16
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $195K
Holders
58
Holding in Top 10
2
Calls
–
Puts
$195K
Top Buyers
| 1 | +$8.6M | |
| 2 | +$4.5M | |
| 3 | +$3.63M | |
| 4 |
Renaissance Technologies
New York
|
+$3.29M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$2.79M |
Top Sellers
| 1 | -$9.68M | |
| 2 | -$3.69M | |
| 3 | -$3.58M | |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$3.26M |
| 5 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$2.51M |